Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kristin Higgins
Observed name:
K. Higgins
Institutions:
City Of Hope National Medical Center,
Emory University,
Emory University Hospital,
Winship Cancer Institute
Observed institutions:
City Of Hope National Medical Center,
Emory University,
Emory University Hospital,
City of Hope,
Winship Cancer Institute
ORCID:
0000-0003-1496-9878
Observed ORCID:
0000-0003-1496-9878
OpenAlex ID:
A5131208055
Computational pathology features of immune architecture predict clinically relevant outcomes in small-cell lung cancer (SCLC)
2026
·
Cristian Barrera
, Prantesh Jain
, et al.
·
npj Precision Oncology
·
1
The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
·
Cancer Research Communications
·
1
PDF
927MO Osimertinib (osi) before and after chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFRm NSCLC: Phase II NEOLA study interim analysis (IA)
2025
·
M. Chen
, H. Wakelee
, et al.
·
Annals of Oncology
·
1
Supplementary Table 13 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Figure 5 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Table 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 10 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 11 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Figure 4 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 8 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Figure 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Table 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Data from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Figure 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Figure 6 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Table 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 4 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 7 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 6 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 5 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Supplementary Table 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026
·
Joanne B. Weidhaas
, Jonathan Harris
, et al.
Show more works
View as search
Works count:
30
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type